Community/Retail

The FDA is expected to review the safety and efficacy data package from Moderna's COVID-19 vaccine candidate on December 17, which could lead to an EUA being issued this week.

As administration of COVID-19 begins, pharmacies are preparing to vaccinate millions of people, not only once but twice.

Learn how you and your staff can help patients differentiate between common cough/cold symptoms and COVID-19 while also offering additional educational resources.

Pharmacy Times® interviewed Signe Pringle, the assistant secretary for the Maryland Department of Commerce, on a signed partnership between Quebec and Maryland to foster collaboration around health science research during COVID-19 and beyond.

Supreme Court ruling clears the way for states to pass laws that protect pharmacies from predatory reimbursement practices by PBMs.

Individuals who reported zero or fewer live births and those who reported many live births had markers of quicker aging than those who reported 3 or 4 births.

Distribution of the first 2.9 million doses of the COVID--19 vaccine jointly developed by Pfizer and BioNTech are expected to begin within hours of the FDA’s decision.

A member of the FDA’s expert advisory committee who voted in favor of Pfizer and BioNTech’s COVID-19 vaccine said that distribution of the first vaccines to high priority populations in the United States could begin as early as Monday.

Genetic predisposition is only part of the pre-eclampsia risk.

There are compelling reasons to use sodium-glucose cotransporter-2 (SGLT2) inhibitors for the treatment of type 2 diabetes, according to a session at the 2020 ASHP Midyear Clinical Meeting and Exhibition.

Paracelsus referred to the drug as the “stone of immortality,” which may have been the impetus for his fine-tuning it further. Later, Thomas Sydenham created his own version in the 1600s with the important addition of alcohol.

The objective of the study was to increase awareness among pharmacists about products for which unfounded claims have been made regarding prevention of severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infections.

Supreme Court decision establishes that states do have the right to regulate pharmacy benefit managers in managed care organizations.

Direct-to-consumer COVID-19 kit allows for anyone over 18 years of age to perform a nasal swab on themselves and send the sample off for testing.

According to investigators, most medications should be stored at room temperature, between 68 and 77 degrees Fahrenheit.

Variability in prescrption handoffs might make the difference between a patient who is adherent or not.

Until COVID-19 vaccines are widely available, Anthony Fauci, MD, said the importance of public health measures cannot be understated.

Specifically, in rural settings, growing primary care provider shortages impact patient access to care.

If current drug pricing trends continue, cost-related non-adherence to therapy will result in the premature deaths of 112,000 Medicare beneficiaries per year.

The tau protein can help identify Alzheimer disease before cognitive decline begins.

Grief can affect an organization as well as an individual; however, there are management strategies that can be used for addressing these issues.

Accurate blood pressure measurement is crucial to diagnose hypertension and guide treatment.

Acquired hemophilia A is a rare bleeding disorder caused by autoantibodies that inhibit coagulation factor VIII (FVIII), and the disorder is understudied given its rarity and the lack of randomized prospective trials to guide therapy.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses closing thoughts on the results of the study and its implications for future treatment options for patients with relapsed/refractory multiple myeloma.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses what the implications of the high rate of dose holds that occurred in the study were, and whether there any plans to address this concern in the future.

Hagop Kantarjian, MD, of the University of Texas MD Anderson Cancer Center, discusses what his team’s plans are for the evaluation of ponatinib during the remaining portion of the OPTIC trial, which is currently ongoing.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses whether the treatment emergent adverse events (AEs) were consistent with the known safety profiles for belantamab mafodotin and pomalidomide.

Suzanne Trudel, MD, MSC, FRCPC, of the University of Toronto and the Princess Margaret Cancer Centre in Toronto, discusses common adverse events (AEs) observed in patients with relapsed/refractory multiple myeloma following treatment with belantamab mafodotin in combination with pomalidomide and dexamethasone.